Chemotherapy research for metastatic prostate cancer - Wikidata - wikimedia - TriplyDB

Chemotherapy research for metastatic prostate cancer

Chemotherapy research for metastatic prostate cancer

http://www.wikidata.org/entity/Q28071468

about

Safety and Efficacy of First-Line Treatments for Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Indirect Comparison.

P2860

Q55380001-4BABF5A8-0093-44B3-84E8-A560894990E8

P2860

Chemotherapy research for metastatic prostate cancer

http://www.wikidata.org/entity/Q28071468

description

2016 nî lūn-bûn

@nan

2016 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2016 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

name

Chemotherapy research for metastatic prostate cancer

@ast

Chemotherapy research for metastatic prostate cancer

@en

Chemotherapy research for metastatic prostate cancer

@nl

type

label

Chemotherapy research for metastatic prostate cancer

@ast

Chemotherapy research for metastatic prostate cancer

@en

Chemotherapy research for metastatic prostate cancer

@nl

prefLabel

Chemotherapy research for metastatic prostate cancer

@ast

Chemotherapy research for metastatic prostate cancer

@en

Chemotherapy research for metastatic prostate cancer

@nl

P1433

Q28071468-4607CCDD-FE3C-4825-A4E6-35297BFF6ED3

P1476

Q28071468-E68BD336-BC46-4C02-9086-EC0AE69F088C

P2093

Q28071468-18E0280F-560A-4989-ADBE-DCB57F8F9706

Q28071468-53ED62EB-5703-4721-A0DA-806900FBAFE7

P2860

Q28071468-4C9FAA38-B1FA-48B0-B07F-71D9FD7D38B8

Q28071468-6C6BFD04-1559-405A-A8AD-5AD5CE914DC7

Q28071468-739967D7-F9A2-4BD5-8033-E30CF4C42B19

Q28071468-7BA37B59-E489-4BDD-9C3A-5AB9D8EF1CFA

Q28071468-7DD01178-5792-459D-A30C-348F4B680C96

Q28071468-8937E4A6-8894-41E2-BCF6-C800C77674FE

Q28071468-CBEA3E1B-AB3D-4D02-AD35-73C670C63DCB

Q28071468-DD895296-AF23-4964-9749-CA2F2C2E979E

Q28071468-E95D0B20-CD3A-4D19-8177-20A0402C687B

Q28071468-FE323B1F-7B3B-4B21-89FC-3D5EB8DEC4DE

P304

Q28071468-97321259-DE96-4C1F-8C44-5B8FEEE526BA

P31

Q28071468-0DC70C36-0145-438F-8A38-7E52A03E9493

P356

Q28071468-DD44129E-0F26-46E8-B7C7-8D63FCF7AD88

P407

Q28071468-1D512802-2C69-4E86-B64E-47C5F3F73D35

P433

Q28071468-94F4FCA5-CCE1-4D66-B01A-A9EF4C97CD30

P478

Q28071468-28445D2C-B326-48F4-A182-3362048917C2

P577

Q28071468-F82CBD79-5600-46C0-868E-BE2D1A50936F

P698

Q28071468-4FED4947-1B8B-4507-A369-11F54F37117A

P921

Q28071468-04C6D7A3-3CCD-48F7-B2C7-78E3908FE6A2

P932

Q28071468-5EFE6571-61B5-43AE-B52B-4611DB3C91DC

P356

P1433

Canadian Urological Association journal = Journal de l'Association des urologues du Canada

P1476

Chemotherapy research for metastatic prostate cancer

@en

P2093

Anil Kapoor

http://www.w3.org/2001/XMLSchema#string

Sebastien J. Hotte

http://www.w3.org/2001/XMLSchema#string

P2860

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial

Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer

Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial.

Measuring the side effects of taxane therapy in oncology: the functional assesment of cancer therapy-taxane (FACT-taxane).

Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16.

Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial.

Is there a role for the assessment of health-related quality of life in the clinical evaluation of novel cytostatic agents?: Commentary re: P. M. LoRusso, Improvements in quality of life and disease-related symptoms in phase I trials of the selectiv

Overcoming chemotherapy resistance in prostate cancer.

P304

S140-S143

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.5489/CUAJ.4055

http://www.w3.org/2001/XMLSchema#string

P407

P433

7-8Suppl3

http://www.w3.org/2001/XMLSchema#string

P478

10

http://www.w3.org/2001/XMLSchema#string

P577

2016-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27895810

http://www.w3.org/2001/XMLSchema#string

P921

P932

5120982

http://www.w3.org/2001/XMLSchema#string